How many insider trades does FilingIQ track for CADL?

FilingIQ tracks 150 Form 4 insider transactions for CADL (Candel Therapeutics, Inc.), covering filings from Jul 27, 2021 onwards. 4 of those were filed in the last 90 days.

Are CADL insiders net buyers or net sellers?

Across the full Form 4 history for CADL, 24 transactions (16%) were open-market purchases and 39 (26%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does CADL insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is CADL in?

Candel Therapeutics, Inc. (CADL) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $282.73M.

CADL insider trading

NasdaqGM Healthcare

Candel Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

150

Last 90 days

Buys / sells

16% / 26%

Market cap

$282.73M

About Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Company website: www.candeltx.com

CADL insider activity at a glance

FilingIQ has scored 150 insider transactions for CADL since Jul 27, 2021. The most recent filing in our index is dated Mar 31, 2026.

Across the full history, 24 open-market purchases and 39 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on CADL insider trades is 59.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live CADL trades on FilingIQ Raw filings on SEC EDGAR

Latest CADL Form 4 filings

Tak Paul Peter Chief Executive Officer

S Nov 29, 2024

Tyagarajan Seshu Chief Technology Officer

S Nov 29, 2024

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for CADL?: FilingIQ tracks 150 Form 4 insider transactions for CADL (Candel Therapeutics, Inc.), covering filings from Jul 27, 2021 onwards. 4 of those were filed in the last 90 days.
Are CADL insiders net buyers or net sellers?: Across the full Form 4 history for CADL, 24 transactions (16%) were open-market purchases and 39 (26%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does CADL insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is CADL in?: Candel Therapeutics, Inc. (CADL) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $282.73M.

Methodology & sources

Every CADL insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.